Portal de Periódicos da CAPES

Influence of Ethanol and Gender on Methylphenidate Pharmacokinetics and Pharmacodynamics

2007; Wiley; Volume: 81; Issue: 3 Linguagem: Inglês

10.1038/sj.clpt.6100082

1532-6535

Kennerly S. Patrick, Arthur B. Straughn, Robin Minhinnett, Sharon D. Yeatts, Amy E. Herrin, C. Lindsay DeVane, Robert Malcolm, Gregory C. Janis, John S. Markowitz,

Neurotransmitter Receptor Influence on Behavior

This study explores the hypotheses that: (1) ethanol will interact with dl-Methylphenidate (MPH) to enantioselectively elevate plasma d-MPH, and primarily yield l-ethylphenidate as a transesterification metabolite; (2) women will exhibit lower relative bioavailability of MPH than men; and (3) sex-dependent differences in subjective effects will exist. dl-MPH HCl (0.3 mg/kg) was administered orally 30 min before ethanol, 30 min after ethanol (0.6 gm/kg), or without ethanol, in a randomized, normal subject three-way crossover study of 10 men and 10 women. Pharmacokinetic parameters were compared. Subjective effects were recorded using visual analog scales. One subject was a novel poor MPH metabolizer whose data were analyzed separately. Ethanol after or before MPH significantly (P<0.0001) elevated the geometric mean for the maximum d-MPH plasma concentration (Cmax (±SD)) from 15.3 (3.37) ng/ml to 21.5 (6.81) and 21.4 (4.86), respectively, and raised the corresponding geometric mean for the area under the concentration–time curve values from 82.9 (21.7) ng ml/h to 105.2 (23.5) and 102.9 (19.2). l-MPH was present in plasma only at 1–3% of the concentration of d-MPH, except in the poor metabolizer where l-MPH exceeded that of d-MPH. The metabolite l-ethylphenidate frequently exceeded 1 ng/ml in plasma, whereas d-ethylphenidate was detected only in low pg/ml concentrations. Women reported a significantly greater stimulant effect than men when questioned “Do you feel any drug effect?” (P<0.05), in spite of lower mean plasma d-MPH area under the response–time curves in women. Ethanol elevates plasma d-MPH Cmax and area under the concentration–time curve by approximately 40% and 25%, respectively. If the poor metabolizer of MPH proves to be a distinct phenotype, determining the genetic mechanism may be of value for individualizing drug therapy. The more pronounced stimulant effects experienced by women have sex-based abuse liability implications. Clinical Pharmacology & Therapeutics (2007) 81, 346–353. doi:10.1038/sj.clpt.6100082